Formerly known as APC Biotechnology Services, Inc., and then Clarassance, Inc. in December 2014, the firm became Therabron Therapeutics. The firm is a privately held, clinical-stage, biopharmaceutical corporation developing a new class of drugs from the secretoglobin family of proteins. The firm's lead product is a proprietary preparation of recombinant human CC10 protein (rhCC10), having immediate clinical applications in respiratory diseases. The company is developing rhCC10 in persistent sinusitis, severe influenza-like illness (ILI), COPD, and neonatal bronchopulmonary dysplasia. A second secretoglobin protein product, based on the SCGB3A2 protein (CG1011), has completed proof of concept studies in pulmonary fibrosis. Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native CC10 protein in patients. Therabon is tackling development of a pharmaceutical therapy to replace CC10 with the synthetic version (rhCC10) in respiratory diseases characterized by inflammation and pre-existing CC10 deficiency. Restoration of CC10 function using rhCC10 has the potential to modify, or even rehabilitate, inflamed airways in diseases like asthma, chronic or recurrent sinusitis, COPD, and pulmonary fibrosis, rather than just treat the symptoms. RhCC10 has completed two Phase 1 clinical trials in which it demonstrated potent anti-inflammatory activity and significant long-term benefit in premature infants, who are known to lack sufficient native CC10 in their lungs.
